News & Blog
News & Blog
Lexeo Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies
Meet The Community: Stephanie Magness
Meet The Community: Sandra Johnson
Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia
Meet The Community: Jeremy Cowart
Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update
Meet The Community: Corinne
Meet The Community: Frank Van Linden
PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia
Meet The Community: Zach Gault
